Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 3
1965 1
1966 1
1967 1
1969 4
1970 3
1971 4
1972 5
1973 1
1974 1
1975 1
1976 4
1978 3
1979 1
1980 2
1981 3
1982 1
1983 3
1984 2
1985 4
1986 3
1987 5
1988 4
1989 4
1990 6
1991 3
1992 4
1993 11
1994 8
1995 13
1996 19
1997 25
1998 26
1999 32
2000 43
2001 41
2002 46
2003 49
2004 51
2005 74
2006 58
2007 107
2008 114
2009 138
2010 163
2011 183
2012 173
2013 221
2014 268
2015 269
2016 258
2017 258
2018 279
2019 323
2020 366
2021 415
2022 493
2023 338
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

4,409 results

Results by year

Filters applied: . Clear all
Page 1
Poly(ADP-ribose) promotes toxicity of C9ORF72 arginine-rich dipeptide repeat proteins.
Gao J, Mewborne QT, Girdhar A, Sheth U, Coyne AN, Punathil R, Kang BG, Dasovich M, Veire A, DeJesus Hernandez M, Liu S, Shi Z, Dafinca R, Fouquerel E, Talbot K, Kam TI, Zhang YJ, Dickson D, Petrucelli L, van Blitterswijk M, Guo L, Dawson TM, Dawson VL, Leung AKL, Lloyd TE, Gendron TF, Rothstein JD, Zhang K. Gao J, et al. Among authors: kang bg. Sci Transl Med. 2022 Sep 14;14(662):eabq3215. doi: 10.1126/scitranslmed.abq3215. Epub 2022 Sep 14. Sci Transl Med. 2022. PMID: 36103513 Free PMC article.
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, Lonardi S, Scartozzi M, Iavarone M, Di Costanzo GG, Marra F, Soldà C, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Pressiani T, Nishida N, Iwamoto H, Sakamoto N, Ryoo BY, Chon HJ, Claudia F, Niizeki T, Sho T, Kang B, D'Alessio A, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimur T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Pedica F, De Cobelli F, Ratti F, Aldrighetti L, Kudo M, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: kang b. ESMO Open. 2022 Dec;7(6):100591. doi: 10.1016/j.esmoop.2022.100591. Epub 2022 Oct 6. ESMO Open. 2022. PMID: 36208496 Free PMC article.
Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery.
Labadie JG, Ibrahim SA, Worley B, Kang BY, Rakita U, Rigali S, Arndt KA, Bernstein E, Brauer JA, Chandra S, Didwania A, DiGiorgio C, Donelan M, Dover JS, Galadari H, Geronemus RG, Goldman MP, Haedersdal M, Hruza G, Ibrahimi OA, Kauvar A, Kelly KM, Krakowski AC, Miest R, Orringer JS, Ozog DM, Ross EV, Shumaker PR, Sobanko JF, Suozzi K, Taylor MB, Teng JMC, Uebelhoer NS, Waibel J, Wanner M, Ratchev I, Christensen RE, Poon E, Miller CH, Alam M. Labadie JG, et al. Among authors: kang by. JAMA Dermatol. 2022 Oct 1;158(10):1193-1201. doi: 10.1001/jamadermatol.2022.3234. JAMA Dermatol. 2022. PMID: 35976634
Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling.
Ai J, Guo J, Zhang H, Zhang Y, Yang H, Lin K, Song J, Fu Z, Fan M, Zhang Q, Wang H, Zhao Y, He Z, Cui A, Zhou Y, Wu J, Zhou M, Yuan G, Kang B, Zhao N, Xu Y, Zhu M, Wang Y, Zhang Z, Jiang N, Qiu C, Xu C, Zhang W. Ai J, et al. Among authors: kang b. Cell Discov. 2022 Oct 21;8(1):114. doi: 10.1038/s41421-022-00480-5. Cell Discov. 2022. PMID: 36270988 Free PMC article.
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ. Lee CK, et al. Among authors: kang b. Lancet Gastroenterol Hepatol. 2023 Jan;8(1):56-65. doi: 10.1016/S2468-1253(22)00335-1. Epub 2022 Oct 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36328033 Clinical Trial.
4,409 results